secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2026-03-25T23:59:59+00:00
Accession:  0001104659-26-034611
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio CFO Mark Guerin departs; CEO Maria Maccecchini appointed acting CFO
-------------------------------------------------------------------------------

- Mark Guerin left as CFO effective March 23, 2026; departure unrelated to any disagreement with the company.
- CEO Maria Maccecchini will serve as Acting CFO until a permanent replacement is identified.
- No financial impact disclosed; company continues operations with existing management.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465926034611/0001104659-26-034611-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465926034611/tm269828d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-034611

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer